Moderna shares rose after the company said its mRNA-based skin cancer vaccine, used with Merck Keytruda, reduced the risk of recurrence or death by 49% at five years in high-risk melanoma patients. The update builds on earlier results, with more data set to be presented at an upcoming medical meeting.